Janney Montgomery Scott LLC Has $3.49 Million Stock Position in Aquestive Therapeutics, Inc. $AQST

Janney Montgomery Scott LLC reduced its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 0.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,053,060 shares of the company’s stock after selling 6,700 shares during the quarter. Janney Montgomery Scott LLC owned about 1.06% of Aquestive Therapeutics worth $3,486,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AQST. Millennium Management LLC lifted its stake in shares of Aquestive Therapeutics by 111.2% in the fourth quarter. Millennium Management LLC now owns 87,227 shares of the company’s stock worth $311,000 after acquiring an additional 45,926 shares during the period. Trust Point Inc. lifted its stake in shares of Aquestive Therapeutics by 69.9% in the first quarter. Trust Point Inc. now owns 23,396 shares of the company’s stock worth $68,000 after acquiring an additional 9,625 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Aquestive Therapeutics in the first quarter worth approximately $33,000. Harvey Capital Management Inc. lifted its stake in shares of Aquestive Therapeutics by 86.8% in the first quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company’s stock worth $1,449,000 after acquiring an additional 232,180 shares during the period. Finally, SBI Securities Co. Ltd. lifted its stake in shares of Aquestive Therapeutics by 47.0% in the first quarter. SBI Securities Co. Ltd. now owns 47,553 shares of the company’s stock worth $138,000 after acquiring an additional 15,205 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 3.9%

NASDAQ AQST opened at $6.20 on Thursday. The company has a market cap of $618.26 million, a price-to-earnings ratio of -8.86 and a beta of 1.77. Aquestive Therapeutics, Inc. has a 52 week low of $2.12 and a 52 week high of $6.43. The business has a 50 day moving average price of $4.65 and a 200-day moving average price of $3.65.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analysts Set New Price Targets

AQST has been the topic of several recent analyst reports. Lifesci Capital raised Aquestive Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 3rd. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Zacks Research raised Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday. Finally, Oppenheimer boosted their price target on Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.50.

Insider Buying and Selling

In related news, COO Cassie Jung sold 62,180 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $5.00, for a total transaction of $310,900.00. Following the completion of the sale, the chief operating officer owned 283,346 shares in the company, valued at approximately $1,416,730. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Peter E. Boyd sold 10,000 shares of the business’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $6.30, for a total value of $63,000.00. Following the completion of the transaction, the insider directly owned 278,323 shares in the company, valued at approximately $1,753,434.90. This represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 178,923 shares of company stock worth $1,006,598. 8.35% of the stock is owned by corporate insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.